27 hasil untuk "Lavaud, Pernelle"
Menampilkan 1–20 · 0,36 detik · RSS
-
Artikel Jurnal Teks lengkap
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
Breast cancers over-express the human epidermal growth factor receptor 2 (HER2) in about 15% of patients. This transmembrane tyrosine kinase receptor activates downstream signaling pathways and leads to proliferation of cancer cells. Trastuzumab, an anti-HER2 monoclonal antibody, improves outcome…
-
Artikel Jurnal Teks lengkap
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
BACKGROUND: Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic castrate-resistant prostate cancer (mCRPC), thanks to next-generation androgen…
-
Artikel Jurnal Teks lengkap
Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
BACKGROUND: ROS1 tyrosine kinase inhibitors (TKIs) have showed activity and efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC). In the clinical practice, besides the utilization of crizotinib, less is known about the best treatment strategies involving additional, new-generation TKIs…
-
Artikel Jurnal Teks lengkap
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Until recently, continuing androgen deprivation therapy (ADT) and closely monitoring patients until evolution towards metastatic castration-resistant prostate cancer (CRPC) were recommended in men with non-metastatic CRPC (nmCRPC). Because delaying the development of metastases and symptoms in…
-
Artikel Jurnal Teks lengkap
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
SIMPLE SUMMARY: The current review summarizes the new potential treatment strategies for patients with early-stage non-small cell lung cancer with immunotherapy and targeted therapies and defines the current challenges for making treatment decisions with these approaches in daily practice…
-
Artikel Jurnal Teks lengkap
Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography
Lung cancer is the third most frequent cancer in France. It has a poor prognosis when patients are diagnosed at advanced stages. Low-dose computed tomography (LDCT) can detect early-stage cancer. In addition, blood-based biomarkers could help select patients for lung cancer screening or manage…
-
Artikel Jurnal Teks lengkap
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
In this case report, we describe a case of sequential acquired CCDC6-RET fusion and BRAF V600E mutation observed in a patient with EGFR-mutated NSCLC treated with osimertinib and with combined selpercatinib and osimertinib. The discovery of genomic resistance mechanisms was facilitated by serial…
-
Artikel Jurnal Teks lengkap
Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
INTRODUCTION: The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolution. We evaluated the outcomes after SBRT in…
-
Artikel Jurnal Teks lengkap
Concomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non–Small-Cell Lung Cancer
IMPORTANCE: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy. OBJECTIVE: To explore the association of comedications with overall survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC). DESIGN, SETTING, AND…
-
Artikel Jurnal Teks lengkap
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Gatekeeper mutations are identified in only 50% of the cases at resistance to Anaplastic Lymphoma Kinase (ALK)-tyrosine kinase inhibitors (TKIs). Circulating tumor cells (CTCs) are relevant tools to identify additional resistance mechanisms and can be sequenced at the single-cell level. Here, we…
-
Artikel Jurnal Teks lengkap
Treatments Outcomes in Histological Variants and Non-Urothelial Bladder Cancer: Results of a Multicenter Retrospective Study
INTRODUCTION: Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers…
-
Artikel Jurnal Teks lengkap
Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab
IMPORTANCE: Two years of immunotherapy is the standard treatment for most patients with advanced non–small cell lung cancer. However, little is known about postimmunotherapy therapeutic strategies. OBJECTIVE: To describe subsequent treatments and outcomes after pembrolizumab discontinuation…
-
Artikel Jurnal Teks lengkap
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study
BACKGROUND: The efficacy of front-line pembrolizumab has been established in studies that limit treatment duration to 2 years, but decision to stop pembrolizumab after 2 years is often at physician's discretion. ATHENA is a retrospective cohort study using a comprehensive administrative database…
-
Artikel Jurnal Teks lengkap
Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial
INTRODUCTION: DNA damage repair genes are altered in 20–35% of metastatic castration-resistant prostate cancer (mCRPC). Poly-ADP (Adénosine Diphosphate)-ribose polymerase inhibitors (PARPi) showed significant activity for these selected tumors, especially with homologous recombination repair (HRR)…
-
Artikel Jurnal Teks lengkap
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study
BACKGROUND: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort. METHODS: Patients…
-
Artikel Jurnal Teks lengkap
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
SIMPLE SUMMARY: In this study, we measured the plasmatic concentration of Kinase inhibitors (KI) among a population with non-small cell lung cancer (NSCLC) harboring driver genetic alterations. They received erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib)…
-
Artikel Jurnal Teks lengkap
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
SIMPLE SUMMARY: In this report, we studied the role of the LIPI score, a biological score based on 2 factors, derived neutrophils/(leukocytes minus neutrophils) ratio and lactate dehydrogenase, in population with unresectable urothelial cancer treated with immune checkpoint inhibitor (ICI). This…
-
Artikel Jurnal Teks lengkap
Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
SIMPLE SUMMARY: Recently, the introduction of immunotherapy radically changed the therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy. Unfortunately, the small amount of patient benefits from immune-checkpoint inhibitors (ICI) and the prognostic role of…
-
Artikel Jurnal Teks lengkap
AB033. Thymic cancer in France: a comprehensive analysis of incidence based on French National Healthcare Data—a retrospective observational study
BACKGROUND: Thymic epithelial tumors (TETs) are rare malignancies with an estimated incidence of 0.18 cases per 100,000 person-years in the European Union. Comprehensive national data remain limited. This study aimed to evaluate the epidemiology, clinical characteristics, and associated conditions…
-
Artikel Jurnal Teks lengkap
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs) are standard treatment for advanced/metastatic urothelial cancer (a/mUC) following progression on platinum agents. Traditionally, PDL-1 expression has been utilised to predict response to ICIs; however, this is not a robust selection marker…